Shares of Viewray Inc (NASDAQ:VRAY) have received a consensus rating of “Buy” from the thirteen research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.33.

VRAY has been the topic of several recent research reports. BidaskClub upgraded shares of Viewray from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 15th. Northland Securities reissued a “buy” rating and issued a $5.00 price target on shares of Viewray in a research report on Monday, August 19th. Cantor Fitzgerald set a $13.00 price target on shares of Viewray and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Mizuho reaffirmed a “buy” rating and set a $9.00 price objective on shares of Viewray in a report on Sunday, August 11th. Finally, ValuEngine lowered Viewray from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th.

VRAY stock traded up $0.04 during midday trading on Friday, hitting $3.83. The stock had a trading volume of 366,721 shares, compared to its average volume of 2,076,071. The firm has a market capitalization of $373.24 million, a price-to-earnings ratio of -3.90 and a beta of 1.06. Viewray has a 52 week low of $2.76 and a 52 week high of $10.44. The stock has a 50-day simple moving average of $5.48 and a 200 day simple moving average of $7.59. The company has a current ratio of 4.01, a quick ratio of 3.01 and a debt-to-equity ratio of 0.55.

Viewray (NASDAQ:VRAY) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.09). Viewray had a negative net margin of 128.13% and a negative return on equity of 67.02%. The business had revenue of $30.17 million during the quarter, compared to the consensus estimate of $25.92 million. During the same period last year, the firm earned ($0.30) EPS. The company’s quarterly revenue was up 83.5% compared to the same quarter last year. On average, equities analysts forecast that Viewray will post -1.18 EPS for the current year.

In other news, insider James F. Dempsey sold 5,146 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $8.63, for a total transaction of $44,409.98. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Shahriar Matin purchased 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was acquired at an average cost of $4.02 per share, with a total value of $241,200.00. The disclosure for this purchase can be found here. Insiders have sold a total of 306,175 shares of company stock valued at $1,235,805 in the last quarter. 15.48% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of VRAY. BNP Paribas Arbitrage SA increased its holdings in shares of Viewray by 57,004.3% in the first quarter. BNP Paribas Arbitrage SA now owns 13,134 shares of the company’s stock valued at $97,000 after purchasing an additional 13,111 shares in the last quarter. Candriam Luxembourg S.C.A. increased its stake in shares of Viewray by 1,204.8% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 132,857 shares of the company’s stock valued at $982,000 after buying an additional 122,675 shares during the period. Stephens Inc. AR bought a new stake in shares of Viewray during the first quarter worth $117,000. Wrapmanager Inc. raised its position in shares of Viewray by 22.6% during the first quarter. Wrapmanager Inc. now owns 32,902 shares of the company’s stock worth $243,000 after acquiring an additional 6,064 shares during the last quarter. Finally, Brasada Capital Management LP bought a new stake in shares of Viewray during the first quarter worth $218,000.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Read More: Google Finance Portfolio Tips and Tricks

Analyst Recommendations for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with's FREE daily email newsletter.